Erdafitinib has recently been approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC). The current study aimed to evaluate whether erdafitinib inhibits the proliferation in UC inducing authophagy. Our data showed that erdafitinib demonstrated strong toxicity for the T24 and UMUC6 cell lines. Flow cytometry analysis showed that erdafitinib increased the proportion of G0/G1 phase in both T24 and UMUC6 cells. Additionally, Annexin V staining indicated that erdafitinib enhanced the apoptosis of UC cells. Meanwhile, the expression of apoptosis-related proteins was significantly elevated after treatment with erdafitinib. Transwell assay showed that erdafitinib significantly reduced T24 and UMUC6 cell migration and invasion. More importantly, western blot assay showed that erdafitinib induced the expression of autophagy-related proteins. Besides, GFP-LC3 transfection assay and electron microscopy examination showed that erdafitinib could partially diminish 3-methyladenine (3-MA) induced impairment of autophagy in UC cells. In summary, for the first time we showed novel data that erdafitinib inhibited UC cell malignant proliferation inducing cell autophagy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1691/ph.2020.9911 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Erdafitinib exerts the anticancer effect on urothelial carcinoma induction of authophagy.
Pharmazie
May 2020
Department of Urinary Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou;, Email:
Erdafitinib has recently been approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC). The current study aimed to evaluate whether erdafitinib inhibits the proliferation in UC inducing authophagy. Our data showed that erdafitinib demonstrated strong toxicity for the T24 and UMUC6 cell lines.
View Article and Find Full Text PDFPercutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial.
Oncoimmunology
May 2019
Department of Urology, School of Medicine, the University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
: Intravesical bacillus Calmette-Guérin (BCG) is the gold standard immunologic agent for treating patients with high-grade non-muscle invasive bladder cancer (NMIBC). Nevertheless, relapse rates remain high and BCG unresponsive NMIBC often requires bladder removal. Preclinical data suggest that priming with percutaneous BCG vaccine could improve response to intravesical BCG.
View Article and Find Full Text PDFNACC1, as a Target of MicroRNA-331-3p, Regulates Cell Proliferation in Urothelial Carcinoma Cells.
Cancers (Basel)
September 2018
Department of Diagnostic Pathology, Nara Medical University School of Medicine, Nara 634-8521, Japan.
The nucleus accumbens-associated protein 1 (NACC1) is a transcription factor constitutively expressed in the urothelium, where it regulates cell growth, senescence, autophagy, and epithelial-mesenchymal transition. microRNA (miRNA) constitutes a class of small non-coding RNAs which are involved in cell proliferation, differentiation, and progression of tumors. miRNAs and their target molecules are utilized for molecular diagnosis of urothelial carcinoma.
View Article and Find Full Text PDFThe use of short tandem repeat profiling to characterize human bladder cancer cell lines.
J Urol
June 2009
Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Article Synopsis
- Scientists checked if certain cancer cell lines were mixed up by using a special DNA test called short tandem repeat profiling.
- They found that most cell lines were unique, but two of them (UM-UC-2 and T24) were almost the same, which means one might be a mix-up of the other.
- The study showed that this DNA profiling is a great way to make sure cell lines are what they are supposed to be, making research more accurate.
Connexin 26 gene therapy of human bladder cancer: induction of growth suppression, apoptosis, and synergy with Cisplatin.
Hum Gene Ther
December 2001
Department of Urology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
The connexin 26 (Cx26) gene encodes a protein involved in gap junctional intercellular communication and is a putative tumor suppressor. We constructed a Cx26 adenovirus vector (Ad-Cx26) and used it to infect human bladder cancer cell lines UM-UC-3, UM-UC-6, UM-UC-14, and T24. Infection with Ad-Cx26 suppressed the growth of these cell lines in vitro and prevented tumor formation in vivo.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!